ATE393222T1 - Dcr3 polypeptid, ein tnfr homolog - Google Patents
Dcr3 polypeptid, ein tnfr homologInfo
- Publication number
- ATE393222T1 ATE393222T1 AT98948386T AT98948386T ATE393222T1 AT E393222 T1 ATE393222 T1 AT E393222T1 AT 98948386 T AT98948386 T AT 98948386T AT 98948386 T AT98948386 T AT 98948386T AT E393222 T1 ATE393222 T1 AT E393222T1
- Authority
- AT
- Austria
- Prior art keywords
- dcr3
- tnfr
- dcr3 polypeptide
- homologue
- tnfr homologue
- Prior art date
Links
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 title abstract 4
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 title abstract 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title abstract 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Polymerization Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5928897P | 1997-09-18 | 1997-09-18 | |
US9464098P | 1998-07-30 | 1998-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE393222T1 true ATE393222T1 (de) | 2008-05-15 |
Family
ID=26738582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98948386T ATE393222T1 (de) | 1997-09-18 | 1998-09-18 | Dcr3 polypeptid, ein tnfr homolog |
Country Status (13)
Country | Link |
---|---|
US (5) | US20020065210A1 (de) |
EP (1) | EP1015587B1 (de) |
JP (2) | JP4303883B2 (de) |
AT (1) | ATE393222T1 (de) |
AU (2) | AU762959B2 (de) |
CA (1) | CA2303225C (de) |
CY (1) | CY1108175T1 (de) |
DE (1) | DE69839401T2 (de) |
DK (1) | DK1015587T3 (de) |
ES (1) | ES2306480T3 (de) |
IL (3) | IL134578A0 (de) |
PT (1) | PT1015587E (de) |
WO (1) | WO1999014330A1 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
US20040013664A1 (en) * | 1997-01-14 | 2004-01-22 | Gentz Reiner L. | Tumor necrosis factor receptors 6 alpha & 6 beta |
EP1007659B1 (de) | 1997-01-14 | 2007-06-27 | Human Genome Sciences, Inc. | Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta |
WO1999011791A2 (en) * | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
IL134578A0 (en) | 1997-09-18 | 2001-04-30 | Genentech Inc | DcR3 POLYPEPTIDE, A TNFR HOMOLOG |
EP1037908A2 (de) * | 1997-12-16 | 2000-09-27 | Incyte Pharmaceuticals, Inc. | Menschlicher tumor nekrose factor r2-ähnlicher rezeptor |
DE19809978A1 (de) * | 1998-03-09 | 1999-09-16 | Basf Ag | Neuer Rezeptor aus der menschlichen Lunge |
PL343847A1 (en) * | 1998-03-30 | 2001-09-10 | Lilly Co Eli | Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily |
WO2000037094A2 (en) * | 1998-12-22 | 2000-06-29 | Eli Lilly And Company | Therapeutic applications of flint polypeptides |
JP5550799B2 (ja) | 1999-01-15 | 2014-07-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Tweakのアンタゴニストおよびtweakレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
CN1345329A (zh) * | 1999-03-04 | 2002-04-17 | 人体基因组科学有限公司 | 肿瘤坏死因子受体6α和6β |
AU2495200A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Compositions and methods for the treatment of tumor |
US6835814B1 (en) | 1999-03-30 | 2004-12-28 | Eli Lilly And Company | Protease resistant flint analogs |
EP1165781B1 (de) * | 1999-03-30 | 2007-08-29 | Eli Lilly And Company | Proteaseresistente flint-analoge |
US6965012B1 (en) | 1999-03-30 | 2005-11-15 | Eli Lilly And Company | Flint polypeptide analogs |
AU3739400A (en) * | 1999-03-30 | 2000-10-16 | Eli Lilly And Company | Flint polypeptide analogs |
AU2215300A (en) * | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US6627199B1 (en) | 1999-07-09 | 2003-09-30 | Amgen Inc | Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family |
AU6517800A (en) | 1999-08-04 | 2001-03-05 | Amgen, Inc. | Ntr3, a member of the tnf-receptor supergene family |
MXPA02001264A (es) | 1999-08-04 | 2002-07-22 | Amgen Inc | Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral. |
WO2001018041A2 (en) * | 1999-09-10 | 2001-03-15 | Eli Lilly And Company | Flint proteins and formulations thereof |
AU6891800A (en) * | 1999-09-10 | 2001-04-10 | Eli Lilly And Company | Flint analog compounds and formulations thereof |
AU1915201A (en) * | 1999-12-07 | 2001-06-18 | Eli Lilly And Company | Improving stability of flint through o-linked glycosylation |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
CA2408228A1 (en) * | 2000-05-08 | 2001-11-15 | Biogen, Inc. | Method for promoting neovascularization |
CA2420593A1 (en) * | 2000-08-25 | 2002-03-07 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6.alpha. and 6.beta. |
US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
EP1355945A2 (de) * | 2001-02-01 | 2003-10-29 | Eli Lilly And Company | Glycoformen von flint |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
CN102793921A (zh) | 2002-04-09 | 2012-11-28 | 比奥根艾迪克Ma公司 | 用于治疗tweak 相关病症的方法 |
US20030055221A1 (en) * | 2002-05-07 | 2003-03-20 | Jirong Lu | Stability of flint through o-linked glycosylation |
EP1447093A1 (de) * | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen |
EP2332408B1 (de) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Behandlung neurologischer Störungen |
ES2432564T3 (es) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Tratamiento y evaluación de trastornos inflamatorios |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
WO2007076465A2 (en) * | 2005-12-23 | 2007-07-05 | Diadexus, Inc. | Cln248 antibody compositions and methods of use |
PT2101877E (pt) | 2006-12-28 | 2013-07-22 | Deutsches Krebsforsch | Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
IN2012DN03354A (de) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
JP6297552B2 (ja) | 2012-07-18 | 2018-03-20 | アポジェニックス アーゲー | Mdsの治療のための、cd95シグナル伝達経路阻害剤 |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
CA2884313C (en) | 2012-12-13 | 2023-01-03 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
CN106132436B (zh) | 2014-02-21 | 2021-06-15 | Ibc药品公司 | 通过诱导对trop-2表达细胞的免疫应答的疾病疗法 |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
WO2015200260A1 (en) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
ES2892525T3 (es) | 2014-10-07 | 2022-02-04 | Immunomedics Inc | Uso neoadyuvante de conjugados anticuerpo-fármaco |
EP3076179A1 (de) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnose und behandlung von minderwertigen glioma |
EP3286224A4 (de) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen |
JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
EP3316885B1 (de) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antikörper-sn-38-immunkonjugate mit einem cl2a-linker |
TW202124425A (zh) * | 2019-09-13 | 2021-07-01 | 日商協和麒麟股份有限公司 | DcR3改型體 |
CN115023270A (zh) | 2019-11-27 | 2022-09-06 | 迈斯特治疗公司 | 使用调节剂产生肿瘤反应性t细胞组合物的方法 |
JPWO2022239720A1 (de) | 2021-05-10 | 2022-11-17 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
WO1989005859A1 (en) | 1987-12-21 | 1989-06-29 | The Upjohn Company | Agrobacterium mediated transformation of germinating plant seeds |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
US5206161A (en) * | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
EP1007659B1 (de) * | 1997-01-14 | 2007-06-27 | Human Genome Sciences, Inc. | Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta |
US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
US5885800A (en) * | 1997-02-04 | 1999-03-23 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor, TR4 |
AU9013998A (en) | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
EP1019502A2 (de) | 1997-08-06 | 2000-07-19 | Regeneron Pharmaceuticals, Inc. | Humane waisenrezeptor ntr-1 |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
IL134578A0 (en) | 1997-09-18 | 2001-04-30 | Genentech Inc | DcR3 POLYPEPTIDE, A TNFR HOMOLOG |
WO1999026977A1 (en) | 1997-11-24 | 1999-06-03 | Biogen, Inc. | Novel receptors opg-2 |
EP1037908A2 (de) | 1997-12-16 | 2000-09-27 | Incyte Pharmaceuticals, Inc. | Menschlicher tumor nekrose factor r2-ähnlicher rezeptor |
US6297367B1 (en) * | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
DE19809978A1 (de) | 1998-03-09 | 1999-09-16 | Basf Ag | Neuer Rezeptor aus der menschlichen Lunge |
PL343847A1 (en) | 1998-03-30 | 2001-09-10 | Lilly Co Eli | Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily |
ATE458050T1 (de) | 1998-12-01 | 2010-03-15 | Genentech Inc | Promotion oder inhibition von angiogenese und kardiovaskularisation |
CN1345329A (zh) | 1999-03-04 | 2002-04-17 | 人体基因组科学有限公司 | 肿瘤坏死因子受体6α和6β |
EP1220905A2 (de) | 1999-03-08 | 2002-07-10 | Genentech Inc. | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
EP1165781B1 (de) | 1999-03-30 | 2007-08-29 | Eli Lilly And Company | Proteaseresistente flint-analoge |
AU3739400A (en) | 1999-03-30 | 2000-10-16 | Eli Lilly And Company | Flint polypeptide analogs |
AU6517800A (en) * | 1999-08-04 | 2001-03-05 | Amgen, Inc. | Ntr3, a member of the tnf-receptor supergene family |
TW528801B (en) | 2000-12-05 | 2003-04-21 | Anawrahta Biotech Co Ltd | Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof |
CN102786631B (zh) * | 2012-08-16 | 2014-05-14 | 京东方科技集团股份有限公司 | 光敏性碱可溶性树脂、其制备方法及彩色光刻胶 |
-
1998
- 1998-09-18 IL IL13457898A patent/IL134578A0/xx unknown
- 1998-09-18 WO PCT/US1998/019661 patent/WO1999014330A1/en active Application Filing
- 1998-09-18 CA CA2303225A patent/CA2303225C/en not_active Expired - Lifetime
- 1998-09-18 JP JP2000511869A patent/JP4303883B2/ja not_active Expired - Lifetime
- 1998-09-18 PT PT98948386T patent/PT1015587E/pt unknown
- 1998-09-18 AU AU94970/98A patent/AU762959B2/en not_active Expired
- 1998-09-18 DK DK98948386T patent/DK1015587T3/da active
- 1998-09-18 DE DE69839401T patent/DE69839401T2/de not_active Expired - Lifetime
- 1998-09-18 AT AT98948386T patent/ATE393222T1/de active
- 1998-09-18 EP EP98948386A patent/EP1015587B1/de not_active Expired - Lifetime
- 1998-09-18 ES ES98948386T patent/ES2306480T3/es not_active Expired - Lifetime
-
2000
- 2000-02-16 IL IL134578A patent/IL134578A/en not_active IP Right Cessation
-
2001
- 2001-06-28 US US09/894,924 patent/US20020065210A1/en not_active Abandoned
- 2001-06-28 US US09/896,096 patent/US6764679B2/en not_active Expired - Lifetime
-
2003
- 2003-06-06 US US10/456,819 patent/US20040014176A1/en not_active Abandoned
- 2003-10-10 AU AU2003252913A patent/AU2003252913A1/en not_active Abandoned
- 2003-10-17 US US10/688,132 patent/US20040175791A1/en not_active Abandoned
-
2008
- 2008-07-03 CY CY20081100700T patent/CY1108175T1/el unknown
- 2008-09-04 IL IL193919A patent/IL193919A0/en unknown
- 2008-10-14 US US12/287,735 patent/US20100080793A1/en not_active Abandoned
-
2009
- 2009-02-12 JP JP2009030533A patent/JP5153679B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU9497098A (en) | 1999-04-05 |
US20040175791A1 (en) | 2004-09-09 |
JP2009159970A (ja) | 2009-07-23 |
PT1015587E (pt) | 2008-07-31 |
AU2003252913A1 (en) | 2003-11-06 |
US20100080793A1 (en) | 2010-04-01 |
WO1999014330A1 (en) | 1999-03-25 |
JP5153679B2 (ja) | 2013-02-27 |
EP1015587A1 (de) | 2000-07-05 |
IL134578A (en) | 2010-06-16 |
IL134578A0 (en) | 2001-04-30 |
US20020061559A1 (en) | 2002-05-23 |
DK1015587T3 (da) | 2008-08-25 |
WO1999014330A8 (en) | 1999-05-27 |
AU762959B2 (en) | 2003-07-10 |
CY1108175T1 (el) | 2014-02-12 |
US6764679B2 (en) | 2004-07-20 |
CA2303225C (en) | 2015-03-31 |
US20020065210A1 (en) | 2002-05-30 |
DE69839401D1 (en) | 2008-06-05 |
IL193919A0 (en) | 2009-05-04 |
JP2001516581A (ja) | 2001-10-02 |
EP1015587B1 (de) | 2008-04-23 |
ES2306480T3 (es) | 2008-11-01 |
US20040014176A1 (en) | 2004-01-22 |
JP4303883B2 (ja) | 2009-07-29 |
CA2303225A1 (en) | 1999-03-25 |
DE69839401T2 (de) | 2009-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE393222T1 (de) | Dcr3 polypeptid, ein tnfr homolog | |
ES2137931T3 (es) | Proteinas gdf-1 y uog-1. | |
ATE414775T1 (de) | Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren | |
ATE516354T1 (de) | Apo-2-rezeptor | |
ATE196164T1 (de) | Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend | |
DE69833784D1 (de) | Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren | |
DE69930955D1 (de) | Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren | |
DK1032672T3 (da) | DNA19355-polypeptid, en tumornekrosefaktor-homolog | |
ATE358725T1 (de) | Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren | |
IL135051A0 (en) | Apo-3 ligand polypeptide | |
NO930428L (no) | Proteinstrukturen til plantetoksingelonin | |
ATE443761T1 (de) | Rtd receptor | |
ATE351909T1 (de) | Neue peptidfragmente zur reinigung von proteinen | |
DK0487229T3 (da) | DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet | |
DE60026049D1 (de) | POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN | |
ATE408687T1 (de) | Semaphorin polypeptide | |
MX9708107A (es) | Subunidad alfa de integrina beta 2 humana. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1015587 Country of ref document: EP |